Long-Term Adjuvant Therapy of High-Risk Malignant Melanoma with Interferon α2b
- 1 December 1990
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 95 (6) , S193-S197
- https://doi.org/10.1111/1523-1747.ep12875517
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cutaneous malignant melanoma (arizona cancer center experience). I. Natural history and prognostic factors influencing survival in patients with stage i diseaseCancer, 1988
- Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanomaCancer, 1986
- Interferons in the treatment of malignant melanoma. A review of recent trialsCancer, 1986
- The rising incidence of cutaneous malignant melanomaThe American Journal of Dermatopathology, 1985
- Phase II Results with Recombinant Interferons: Renal Cell Carcinoma and Malignant MelanomaOncology, 1985
- In vitro modulation of human natural killer cell activity by interferon: Generation of adherent suppressor cellsBritish Journal of Cancer, 1984
- Natural cytotoxicity of lymphocytes and monocytes and its augmentation by OK432 in melanoma patientsCancer Immunology, Immunotherapy, 1984
- Active Specific and Active Non-Specific Immunotherapy in Patients with Malignant MelanomaOncology, 1977
- A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorshipBiometrika, 1970
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958